EDITAS MEDICINE, INC. Stock Issued During Period, Value, Purchase of Assets
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EDITAS MEDICINE, INC. stock issued during period, value, purchase of assets for the quarter ending 2018-03-31 was $1.94M.
- EDITAS MEDICINE, INC. stock issued during period, value, purchase of assets for fiscal 2018 was $1.94M.
| Period end | Stock Issued During Period, Value, Purchase of Assets 3 month | Stock Issued During Period, Value, Purchase of Assets 12 month |
|---|---|---|
| 2018-12-31 | $1.94M 10-K · filed 2021-02-26 | |
| 2018-03-31 | $1.94M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |